Medicines can only be effective when delivered to the right cells, tissues, and organs. One of the most promising and effective ways to do this is through Adeno-Associated Viruses (AAVs), the only viral vectors clinically approved for human use. AAVs are prevalent in the human population, benign, and highly robust for transducing cells in the body, making them the therapeutic modality of choice.
The Vector Core @ GIS develops and produces high-grade AAVs for genetic and epigenetic treatments. An academic spin-off of the Molecular Therapeutics Programme, which is constituted by a team from MEL, GIS, NUS, BTI, and SERI, the Vector Core is established as a partnership with the A*STAR Research Support Centre (RSC) to generate high-grade delivery vectors. Find out how we can work together to produce customized and quality-controlled AAV vectors, identify the most efficient AAV serotypes for your cell types via biopanning, deliver genetic cargos that include CRISPR-Cas DNA and RNA -editing systems, and accelerate the translation of gene therapies into clinically relevant disease models.